An updated patent review of IDO1 inhibitors for cancer (2018–2022). (2nd November 2022)

• Record Type: Journal Article
• Authors: Wang, Peng-Fei; Yang, Li-Qiang; Shi, Zhao-Hang; Li, Xue-Min; Qiu, Han-Yue
• Is Part Of: Expert opinion on therapeutic patents. Volume 32:Number 11(2022)
• Page Start: 1145
• Page End: 1159
• Publication Date: 2022-11-02
• Subjects: IDO1 inhibitors -- kynurenine pathway -- anticancer -- immunotherapy; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2022.2151894
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction: Indoleamine 2, 3-dioxygenase 1 (IDO1) is highly related to the immune evasion of a wide range of malignancies due to its role in the immune suppression caused by the depletion of tryptophan (Trp) and the accumulation of kynurenine (Kyn). The combination of IDO1 inhibitors with other treatments represents a promising strategy in immunotherapy, although considerable challenges lie ahead. Areas covered: This review focuses on patent publications searched from Espacenet and Google Scholar, and related to IDO1 inhibitors with potential anti-cancer utilization during the period 2018–2022. Expert opinion: Despite the clinical trial failure of the first-in-class IDO1 inhibitor epacadostat in combination with pembrolizumab, numerous studies have been carried on to pursue more efficient IDO1-based immune-modulating therapeutic solutions. A large number of IDO1 inhibitors with new structures and design concepts have been produced with the impetus of crystallographic studies, and have shown great research potential. The elaboration on the combination of IDO1 inhibitors with other targeting agents, the more precise selection of patients, the identification of more reliable biomarkers for evaluating the IDO1 treatment, and the investigation of possible toxicity, are critical factors to promote IDO1-based immunotherapies from bench to bedside.